CN211785300U - Working electrode of glucose monitoring probe - Google Patents
Working electrode of glucose monitoring probe Download PDFInfo
- Publication number
- CN211785300U CN211785300U CN202020454895.7U CN202020454895U CN211785300U CN 211785300 U CN211785300 U CN 211785300U CN 202020454895 U CN202020454895 U CN 202020454895U CN 211785300 U CN211785300 U CN 211785300U
- Authority
- CN
- China
- Prior art keywords
- glucose
- sensing layer
- monitoring probe
- working electrode
- layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 201
- 239000008103 glucose Substances 0.000 title claims abstract description 201
- 239000000523 sample Substances 0.000 title claims abstract description 120
- 238000012544 monitoring process Methods 0.000 title claims abstract description 106
- 239000012528 membrane Substances 0.000 claims abstract description 51
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000002041 carbon nanotube Substances 0.000 claims abstract description 40
- 229910021393 carbon nanotube Inorganic materials 0.000 claims abstract description 40
- 239000000758 substrate Substances 0.000 claims abstract description 30
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 20
- 229910052751 metal Inorganic materials 0.000 claims abstract description 16
- 239000002184 metal Substances 0.000 claims abstract description 16
- 229920000642 polymer Polymers 0.000 claims abstract description 15
- 239000011248 coating agent Substances 0.000 claims abstract description 7
- 238000000576 coating method Methods 0.000 claims abstract description 7
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 5
- 230000004048 modification Effects 0.000 claims abstract description 5
- 238000012986 modification Methods 0.000 claims abstract description 5
- 238000009792 diffusion process Methods 0.000 claims description 11
- 108010056771 Glucosidases Proteins 0.000 claims description 10
- 102000004366 Glucosidases Human genes 0.000 claims description 10
- 125000003277 amino group Chemical group 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 35
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 2
- 239000010410 layer Substances 0.000 description 103
- 239000008280 blood Substances 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- 210000003722 extracellular fluid Anatomy 0.000 description 17
- 235000019420 glucose oxidase Nutrition 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 12
- 239000004366 Glucose oxidase Substances 0.000 description 11
- 108010015776 Glucose oxidase Proteins 0.000 description 11
- 229940116332 glucose oxidase Drugs 0.000 description 11
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 238000002513 implantation Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- -1 Polyethylene Polymers 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 230000002035 prolonged effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000003487 electrochemical reaction Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229910021607 Silver chloride Inorganic materials 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 229910052741 iridium Inorganic materials 0.000 description 3
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- YPZRHBJKEMOYQH-UYBVJOGSSA-N FADH2 Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004642 Polyimide Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009713 electroplating Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229910021397 glassy carbon Inorganic materials 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910002804 graphite Inorganic materials 0.000 description 2
- 239000010439 graphite Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- 229960005080 warfarin Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102100038358 Prostate-specific antigen Human genes 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000002977 biomimetic material Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005229 chemical vapour deposition Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- VNTXONBESJNLBI-UHFFFAOYSA-N dinonyl decanedioate Chemical compound CCCCCCCCCOC(=O)CCCCCCCCC(=O)OCCCCCCCCC VNTXONBESJNLBI-UHFFFAOYSA-N 0.000 description 1
- 238000001548 drop coating Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007772 electroless plating Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 238000005240 physical vapour deposition Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011112 polyethylene naphthalate Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007650 screen-printing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000679 solder Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
- G01N27/3272—Test elements therefor, i.e. disposable laminated substrates with electrodes, reagent and channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
- A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
- G01N27/3273—Devices therefor, e.g. test element readers, circuitry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/12—Manufacturing methods specially adapted for producing sensors for in-vivo measurements
- A61B2562/125—Manufacturing methods specially adapted for producing sensors for in-vivo measurements characterised by the manufacture of electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/16—Details of sensor housings or probes; Details of structural supports for sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/16—Details of sensor housings or probes; Details of structural supports for sensors
- A61B2562/164—Details of sensor housings or probes; Details of structural supports for sensors the sensor is mounted in or on a conformable substrate or carrier
Abstract
The utility model relates to a working electrode of a glucose monitoring probe, which comprises a basal layer formed on a flexible substrate; the sensing layer is formed on the substrate layer by coating a sensing layer reagent and can chemically react with glucose, the sensing layer reagent comprises a metal polymer, glucosaccharase, carbon nanotubes and a cross-linking agent, the carbon nanotubes are in a hollow column shape and adsorb the metal polymer and the glucosaccharase, amino modification is added to the carbon nanotubes in the sensing layer reagent, and the metal polymer is combined with the carbon nanotubes through covalent bonds; a semi-permeable membrane formed on the sensing layer to control the passage rate of glucose molecules; and a biocompatible membrane formed on the semi-permeable membrane. According to the utility model discloses, can reduce working electrode operating voltage, reduce and disturb, prolong glucose monitor probe's life to improve the reaction sensitivity to glucose.
Description
Technical Field
The utility model relates to a glucose monitor field, concretely relates to working electrode of glucose monitoring probe.
Background
Biosensors are analytical devices that tightly bind biological, biologically derived, or biomimetic materials to optical, electrochemical, temperature, piezoelectric, magnetic, or micromechanical physicochemical sensors or sensing microsystems. To date, the most commercially successful biosensor used is the amperometric enzyme glucose sensor. The market share of amperometric enzyme glucose sensors occupies almost 85% of today's global market. Amperometric enzyme glucose sensors are used to detect diabetes, and the larger the market share, the more people with diabetes are reflected.
Diabetes is a series of metabolic disorder syndromes of sugar, protein, fat, water, electrolyte and the like, and is caused by hypofunction of pancreatic islets, insulin resistance and the like caused by the action of various pathogenic factors such as genetic factors, immune dysfunction, microbial infection and toxins thereof on organisms. If diabetes is not well controlled, complications such as ketoacidosis, lactic acidosis, chronic renal failure and retinopathy may arise. With the increasing incidence of diabetes, diabetes has become a public health problem worldwide.
At present, no radical cure method is available for diabetes, and only a control method is available. For diabetic patients, if the patients can monitor glucose continuously in real time on a daily basis, the occurrence of complications such as low glucose and high glucose in insulin-dependent diabetic patients can be reduced and reduced preferentially.
Typically, glucose monitoring is accomplished by a glucose meter in an amperometric enzyme glucose sensor. The sensing probe of a glucose meter is generally implanted in the body to monitor the glucose concentration in interstitial fluid and the rate of change of the glucose concentration in the surrounding blood flow, metabolism and blood vessels. Studies have shown that glucose concentration changes in interstitial fluid are generally delayed from glucose concentration changes in blood by 2-45 minutes with an average delay of about 6.7 minutes. However, when the glucose concentration in the blood begins to decrease, the glucose concentration in the interstitial fluid first decreases compared to the glucose concentration in the blood, indicating that a decrease in glucose concentration in the interstitial fluid can be predicted for an impending low glucose.
With the development of the technological level, various portable glucose monitors are introduced into the eyes of people, and especially some implantable continuous glucose monitoring devices are favored by diabetics and hospitals. However, implantable continuous glucose meters tend to have a short lifetime and are susceptible to immune reactions in the body and to other impurities in the blood that reduce sensitivity. Therefore, how to better construct the detection device, prolong the service life of the sensing probe of the glucose detector and reduce the influence of other factors becomes the biggest problem at present.
SUMMERY OF THE UTILITY MODEL
The present invention has been made in view of the above circumstances, and an object of the present invention is to provide a working electrode of a glucose monitoring probe, which can prolong the service life of the probe, reduce interference, and improve the sensitivity of the reaction to glucose.
Therefore, an aspect of the present invention provides a working electrode of a glucose monitoring probe, which is characterized in that: a base layer formed on a flexible substrate; a sensing layer formed on the base layer by coating a sensing layer reagent, the sensing layer reagent being capable of chemically reacting with glucose, the sensing layer reagent including a metal polymer, a glucosidase, a carbon nanotube and a cross-linking agent, the carbon nanotube having a hollow columnar shape, the carbon nanotube adsorbing the metal polymer and the glucosidase, the sensing layer reagent including an amino group modification added to the carbon nanotube, the metal polymer being covalently bonded to the carbon nanotube; a semi-permeable membrane formed on the sensing layer, controlling the passage rate of glucose molecules; and a biocompatible membrane formed on the semi-permeable membrane.
In the working electrode of the glucose monitoring probe according to an aspect of the present invention, the sensing layer includes a carbon nanotube. Under the condition, the catalytic action of the carbon nano tube on the glucose reaction reduces the working voltage required by the normal work of the working electrode, and reduces the interference of the current generated by the electrochemical reaction of the electroactive substances under partial high voltage on the working electrode; meanwhile, the reaction sensitivity of the probe to glucose is improved, the linear range of the response of the probe to the glucose is enlarged, and the service life of the probe is prolonged.
Further, in a working electrode of a glucose monitoring probe according to an aspect of the present invention, optionally, the semipermeable membrane includes a diffusion control layer for controlling diffusion of glucose molecules. In this case, when glucose molecules in interstitial fluid or blood enter the semipermeable membrane, the number of glucose molecules is reduced in a certain proportion, so that when glucose reacts with the sensing layer, the sensing layer is in an excessive state, the glucose concentration becomes the only factor for limiting the current of the working electrode, and the linear range of the glucose monitoring probe in monitoring the glucose concentration is expanded.
Additionally, in a working electrode of a glucose monitoring probe according to an aspect of the present invention, optionally, the semipermeable membrane includes an anti-interference layer that blocks non-glucose substances. In this case, other components in the interstitial fluid or blood are prevented from entering the semipermeable membrane, and the influence of other electroactive substances which can also generate current on the working electrode, which results in inaccurate glucose detection results, is avoided.
Further, in the working electrode of the glucose monitoring probe according to an aspect of the present invention, optionally, the sensing layer has a thickness of 0.1 μm to 100 μm. This makes it possible to provide sufficient glucosidase while ensuring sufficient reaction and firm adhesion.
Further, in a working electrode of a glucose monitoring probe according to an aspect of the present invention, optionally, the probe has a lifetime of 1 to 24 days. Therefore, patients with different requirements can conveniently select corresponding service lives.
According to the utility model discloses, can provide the life of an extension probe, reduce the interference and improve the working electrode of glucose monitoring probe to the reaction sensitivity of glucose and manufacturing method thereof.
Drawings
Fig. 1 is a schematic view showing a state of use of a glucose monitoring probe according to an embodiment of the present invention.
Fig. 2 is a schematic configuration diagram showing a glucose monitoring probe according to an embodiment of the present invention.
FIG. 3 is a schematic diagram showing the glucose monitoring probe of FIG. 2 in a bent state.
Fig. 4 is a schematic configuration diagram showing the working electrode of the glucose monitoring probe according to the embodiment of the present invention.
Fig. 5 is a schematic diagram showing that the carbon nanotube of the glucose monitoring probe according to the embodiment of the present invention adsorbs glucosidase.
Fig. 6 is a schematic diagram showing a glucose reaction between a glucose monitoring probe and a tissue according to an embodiment of the present invention.
Fig. 7 is a schematic structural view showing a semipermeable membrane of a working electrode of a glucose monitoring probe according to an embodiment of the present invention.
Fig. 8 is a flowchart illustrating a method for manufacturing a working electrode of a glucose monitoring probe according to an embodiment of the present invention.
Fig. 9 is a flowchart illustrating a method for manufacturing a semipermeable membrane for a working electrode of a glucose monitoring probe according to an embodiment of the present invention.
Detailed Description
Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings. In the following description, the same components are denoted by the same reference numerals, and redundant description thereof is omitted. The drawings are schematic and the ratio of the dimensions of the components and the shapes of the components may be different from the actual ones.
In addition, the headings and the like referred to in the following description of the present invention are not intended to limit the content or scope of the present invention, but only serve as a reminder for reading. Such a subtitle should neither be understood as a content for segmenting an article, nor should the content under the subtitle be limited to only the scope of the subtitle.
Fig. 1 is a schematic view showing a state of use of a glucose monitoring probe according to an embodiment of the present invention. Fig. 2 is a block diagram showing a glucose monitoring probe according to an embodiment of the present invention. FIG. 3 is a schematic diagram showing the glucose monitoring probe of FIG. 2 in a bent state.
In the present embodiment, the glucose monitoring probe 1 may also be referred to as an implantable glucose monitoring probe 1, a probe 1 of a glucose monitor, or a probe 1.
In this embodiment, the portable glucose monitor G may include a glucose monitoring probe 1 and an electronic system 2 connected to the glucose monitoring probe 1. Through implanting the glucose monitoring probe 1 with portable glucose monitor G to the human body such as the body surface of human body, glucose monitoring probe 1 contacts with the interstitial fluid or the blood of body surface to can utilize glucose monitoring probe 1 sensing interstitial fluid's the sensing signal correlated with glucose concentration, through giving electronic system 2 with this glucose concentration signal transmission, thereby can obtain corresponding glucose concentration.
Specifically, a part (particularly, a sensing part) of the glucose monitoring probe 1 may be implanted on, for example, the body surface of a human body to be in contact with interstitial fluid in the body. In addition, another part of the glucose monitoring probe 1 is also connected with an electronic system 2 located outside the body surface. When the portable glucose monitor G is operated, the glucose monitoring probe 1 reacts with tissue fluid or blood in the body to generate a sensing signal (e.g., a current signal) and transmits the sensing signal to the electronic system 2 on the body surface, and the electronic system 2 processes the sensing signal to obtain the glucose concentration. Although fig. 1 shows a position where the glucose monitor probe 1 is disposed on the arm, the present embodiment is not limited thereto, and the glucose monitor probe 1 may be disposed on the abdomen, waist, leg, or the like, for example.
In the present embodiment, the glucose monitoring probe 1 may detect glucose in blood directly or in interstitial fluid. Further, the glucose concentration of interstitial fluid and the glucose concentration of blood are strongly correlated, and the glucose concentration of blood can be obtained from the glucose of interstitial fluid.
In the present embodiment, the glucose monitoring probe 1 may include a substrate S, and a working electrode 10, a reference electrode 20, and a counter electrode 30 (see fig. 2) provided on the substrate S. The glucose monitoring probe 1 further includes a contact 41 connected to the working electrode 10 via a lead, a contact 42 connected to the reference electrode 20 via a lead, and a contact 43 connected to the counter electrode 30 via a lead. Contact 41, contact 42, and contact 43 are all electrical contacts. In some examples, the glucose monitoring probe 1 may be connected with the electronic system 2 via contacts 41, 42, and 43.
In some examples, the substrate S may be a flexible substrate. The flexible substrate may be substantially made of at least one of Polyethylene (PE), polypropylene (PP), Polyimide (PI), Polystyrene (PS), polyethylene terephthalate (PET), polyethylene naphthalate (PEN). In addition, in other examples, the flexible substrate may also be made of substantially metal foil, ultra-thin glass, a single-layer inorganic thin film, a multi-layer organic thin film, a multi-layer inorganic thin film, or the like.
In some examples, the substrate S may also be a non-flexible substrate. The non-flexible substrate may generally comprise a less conductive ceramic, alumina, silica, or the like. In this case, the glucose monitoring probe 1 with the non-flexible substrate may at the same time have a sharp point or a sharp edge, so that the glucose monitoring probe 1 can be implanted in a body surface (e.g., superficial skin layer, etc.) without the need for an auxiliary implantation device (not shown).
In the present embodiment, for convenience of explanation, the glucose monitoring probe 1 may be divided into a connection part 1a and an implantation part 1b (see fig. 3). The line A-A' in FIG. 3 generally shows the approximate location of the skin when the glucose monitoring probe 1 is implanted on the body surface of a tissue, with the attachment portion 1a located outside the body surface and the implanted portion 1b implanted in the body surface.
In addition, in some examples, both the connection portion 1a and the implantation portion 1b may include a flexible substrate, but the present embodiment is not limited thereto, and for example, only the implantation portion 1b may include a flexible substrate while the connection portion 1a includes a non-flexible substrate such as a rigid substrate.
In the present embodiment, the implanted portion 1b of the glucose monitoring probe 1 may be provided to an auxiliary puncture needle (not shown), and the implanted portion 1b may be separable from the puncture needle. Specifically, the piercing needle may be pierced into a tissue (e.g., a superficial skin layer), and then the piercing needle may be withdrawn and separated from the implanted portion 1b of the glucose monitoring probe 1, whereby the implanted portion 1b is left at the superficial skin layer and the electronic system 2 is brought into close contact with the skin surface, and the connection portion 1a (see fig. 3) of the glucose monitoring probe 1 is connected to the electronic system 2 and located at the skin surface. Here, the electronic system 2 may be adhered to the skin surface by an adhesive provided on the substrate S.
In some examples, the puncture needle serving as the auxiliary implanting function may have a notch, and the implanting portion 1b is placed in the notch of the puncture needle. Wherein the puncture needle can be made of stainless steel. In this case, the risk of use of the puncture needle can be reduced, and the puncture needle has sufficient hardness to facilitate skin puncture. Is beneficial to the use of patients. Additionally, in some examples, the needle may also be made of plastic, glass, or metal.
In this embodiment, an auxiliary implanting device (not shown), such as a needle assist device, may be used to pierce the piercing needle into the skin. Under the condition, the puncture depth can be configured in advance by using the needle assisting device, and the purposes of quick puncture, painless puncture and the like are realized by using the needle assisting device, so that the pain of a user is reduced. In addition, one-handed operation is also facilitated by the auxiliary implantation device. However, the present embodiment is not limited thereto, and for example, when the glucose monitoring probe 1 is a rigid substrate as described above, the glucose monitoring probe 1 may be implanted into the skin without the use of a puncture needle.
In the present embodiment, the depth of the glucose monitoring probe 1 implanted under the skin is determined according to the position to be penetrated, and when the fat layer is thick, the glucose monitoring probe is implanted deeper, for example, the abdomen of a human body, and the implantation depth is about 10mm to 15 mm. When the fat layer is thinner, the implantation depth is shallower, for example, at the arm, and the implantation depth is about 5mm to 10 mm.
Fig. 4 is a schematic configuration diagram showing the working electrode 10 of the glucose monitoring probe 1 according to the embodiment of the present invention. Fig. 5 is a schematic diagram showing that the carbon nanotube of the glucose monitoring probe 1 according to the embodiment of the present invention adsorbs glucosidase. Fig. 6 is a schematic diagram showing a glucose reaction between the glucose monitoring probe 1 according to the embodiment of the present invention and a tissue. Fig. 7 is a schematic structural view showing a semipermeable membrane of the working electrode 10 of the glucose monitoring probe 1 according to the embodiment of the present invention.
In the present embodiment, as described above, the implanted portion 1b of the glucose monitoring probe 1 includes the working electrode 10 (see fig. 2 and 3).
In this embodiment, the working electrode 10 may be provided with a basal layer 110, a sensing layer 120, a semi-permeable membrane 130, and a biocompatible membrane 140 (see fig. 4). In some examples, the substrate layer 110, the sensing layer 120, the semi-permeable membrane 130, and the biocompatible membrane 140 may be sequentially stacked.
In the present embodiment, the base layer 110 has conductivity. In some examples, the base layer 110 may be made of at least one selected from gold, glassy carbon, graphite, silver chloride, palladium, titanium, iridium. In this case, the base layer 110 can have good conductivity, and the electrochemical reaction of the base layer 110 can be suppressed, thereby improving the stability of the base layer 110.
In the present embodiment, in some examples, the base layer 110 may be disposed on the substrate S by a deposition or plating method. In some examples, the method of deposition may include physical vapor deposition, chemical vapor deposition, and the like. The plating method may include electroplating, electroless plating, vacuum plating, and the like. Additionally, in some examples, the base layer 110 may also be disposed on the substrate S by screen printing, extrusion, or electrolytic deposition, among others.
In this embodiment, the base layer 110 may be provided on a flexible substrate. Under the condition, the flexible substrate enables the whole product to be light and convenient, has strong shock resistance and reduces foreign body sensation after implantation. In other examples, the base layer 110 may also be disposed on a rigid substrate.
In this embodiment, the sensing layer 120 may be formed on the base layer 110 by coating a sensing layer reagent so as to be capable of chemically reacting with glucose. In some examples, the sensing layer reagents may include a metal polymer, a dextranase, carbon nanotubes 121, and a cross-linking agent. In this case, the sensing layer 120 contains the carbon nanotubes 121, and the catalytic action of the carbon nanotubes 121 on the glucose reaction reduces the working voltage required for the normal operation of the working electrode 10, thereby reducing the interference of the current generated by the electrochemical reaction of the electroactive substance under a high voltage to the working electrode 10.
Generally, carbon nanotubes are coaxial circular tubes having several to several tens of layers, which are mainly composed of carbon atoms arranged in a hexagonal pattern, and the layers are spaced apart from each other by a fixed distance of about 0.34nm, and the diameter is generally 2 to 20 nm.
In some examples, as shown in fig. 5, the carbon nanotube 121 may have a hollow cylindrical shape. Specifically, the carbon nanotube 121 may have a cylindrical or elliptical cylindrical shape. In addition, the carbon nanotube 121 has a strong adsorption capacity to organic substances due to its large surface area and surface hydrophobicity.
In the sensing layer 120, since the carbon nanotubes 121 can adsorb the glucolase and the metal polymer, the carbon nanotubes 121 can sufficiently contact and catalyze the reaction during the glucose reaction, thereby more effectively promoting the glucose reaction.
In this embodiment, the carbon nanotubes 121 may be added as a solvent to the sensing layer reagent. Thus, the sensing layer 120 including the carbon nanotubes 121 can be easily manufactured.
In some examples, the mass percentage of the carbon nanotubes 121 in the sensing layer reagent may be 5 to 10%. This can promote the reaction of the glucosidase more effectively, and reduce the waste of the carbon nanotubes 121.
In some examples, the sensing layer reagent may form the sensing layer 120 by at least one process of spin coating, dip-drawing, drop coating, or spray coating.
In the present embodiment, the sensing layer 120 may be a glucose oxidase sensing layer or a glucose dehydrogenase sensing layer.
Following, in conjunction with FIG. 6, with GOX(FAD) As an example of glucose oxidase, the reaction occurring in the glucose sensing layer 120 will be described.
In the glucose sensing layer 130, when GOX(FAD) when it encounters glucose in the tissue, the following reactions occur:
glucose + GOx (FAD) → gluconolactone + GOx (FADH)2) … … reaction formula (I)
GOx(FADH2)+O2→GOx(FAD)+H2O2… … reaction formula (II)
As can be seen in the above reaction process, oxygen (O) is generated in the chemical reaction2) Is consumed, O2The reaction rate of the reaction of the formula (II) and the formula (I) is limited by O2The reaction with tissue glucose may slow, resulting in failure of the glucose monitoring probe 1. In addition, in the above reaction process, there may be H in the reaction formula (II)2O2Product of (A), H2O2The aggregation may decrease the enzyme activity in the sensing layer 120 and may also cause the glucose monitoring probe 1 to fail. Therefore, by disposing the carbon nanotubes 121 between the base layer 110 and the sensing layer 120, H can be caused to exist by the action of the carbon nanotubes 121 as a catalyst2O2Decomposition reaction occurs, and the specific reaction is as follows:
H2O2→2H++O2+2e-… … reaction formula (III)
The reaction with tissue glucose can be continued by the above reaction formulae (I) to (III). In addition, the carbon nanotube 121 is used to catalyze the hydrogen peroxide decomposition reaction, so that the reaction (III) can be accelerated and the voltage to be applied during the reaction can be reduced, which is beneficial to improving the sensitivity of the glucose monitoring probe 1, prolonging the service life of the glucose monitoring probe 1 and obtaining a low operating voltage. In other words, through the carbon nanotube 121, a high-sensitivity sensing signal of tissue glucose can be continuously obtained, the service time of the glucose monitoring probe 1 is prolonged, and meanwhile, the low working voltage is beneficial to improving the anti-interference performance.
In addition, in some examples, amino modifications may also be added to the carbon nanotubes 121 in the sensing layer reagent. In this case, the metal polymer and the carbon nanotube 121 can be tightly bound to each other by covalent bonds, and thus, the metal polymer and the carbon nanotube can be more stably bound to the glucosidase.
In other examples, graphene, porous titanium dioxide, or conductive organic salts may also be added to the sensing layer reagent. This can promote the reaction of the glucosidase more effectively.
In the present embodiment, the glucose monitoring probe 1 is implanted in the skin of a human body, and can continuously sample the glucose in the blood, convert the glucose into a corresponding current signal, and transmit the current signal to the electronic system 2 outside the body. In addition, sampling refers to a chemical reaction of glucose oxidase or dehydrogenase on the sensing layer 130 with glucose.
In this embodiment, the thickness of the sensing layer 120 may be about 0.1 μm to about 100 μm, preferably about 2 μm to about 10 μm, and in one example, the thickness of the sensing layer 120 may be about 10 μm. Under the condition, the thickness of the glucose oxidase or dehydrogenase is controlled within a certain degree, so that the problems that the adhesion force is reduced due to the fact that the glucose oxidase or dehydrogenase is too much, the materials fall off in vivo, the reaction is insufficient due to the fact that the glucose oxidase or dehydrogenase is too little, and normal glucose concentration information cannot be fed back are solved.
In this embodiment, as shown in fig. 4 and 7, the semi-permeable membrane 130 may be distributed on the sensing layer 120, that is, the semi-permeable membrane 130 may be disposed on the sensing layer 120.
In this embodiment, as shown in fig. 7, the semi-permeable membrane 130 may include a diffusion-controlling layer 131 and a tamper-resistant layer 132 laminated on the diffusion-controlling layer 131. In the semi-permeable membrane 130, the diffusion control layer 131 may control diffusion of glucose molecules, and the interference rejection layer 132 may block diffusion of non-glucose species. Therefore, the tissue fluid or blood component passing through the semipermeable membrane 130 can be reduced, and the interfering substance can be blocked outside the semipermeable membrane 130 by the interference-preventing layer 132. Common interferents may include uric acid, ascorbic acid, acetaminophen, etc., which are ubiquitous in the body.
In other examples, not limited to the example of fig. 7, in the semi-permeable membrane 130, the diffusion control layer 131 may also be laminated on the tamper resistant layer 132. In this case, too, it is possible to reduce the interference of impurities with the working electrode 10, improve the accuracy of the detection result, and prolong the service life of the glucose monitoring probe 1.
In this embodiment, the semi-permeable membrane 130 can control the passage rate of glucose molecules, i.e., the semi-permeable membrane 130 can limit the number of glucose molecules in interstitial fluid or blood that reach the sensing layer 120. Specifically, the diffusion-controlling layer 131 of the semi-permeable membrane 130 can effectively reduce the amount of glucose diffusing into the sensing layer 120 by a certain ratio.
In the present embodiment, the rate of reducing the amount of the entering matter by the diffusion control layer 131 is 10 to 100 times, preferably 30 to 80 times, for example, 50 times. In this case, the amount of glucose diffusing into the sensing layer 120 can be reduced, and a sufficient amount of glucose oxidase or dehydrogenase and other substances participating in the reaction can be ensured, and the glucose concentration becomes a factor for mainly limiting the magnitude of the electrode current, so that the magnitude of the current can correctly reflect the glucose concentration, and the linear range of the glucose monitoring probe 1 can be increased to a large extent.
In this embodiment, a biocompatible membrane 140 may be disposed on the semi-permeable membrane 130 (see fig. 4).
In some examples, the biocompatible membrane 140 may be made of a plant material. The plant material may be sodium alginate, tragacanth gum, pectin, acacia gum, xanthan gum, guar gum, agar, etc., or a derivative of a natural material. Among them, the natural material derivatives may include: starch derivatives, cellulose derivatives, and the like.
In other examples, the biocompatible membrane 140 may also be made of a synthetic material. The synthetic material may be a polyolefin: povidone, polyvinyl alcohol, polyisobutylene pressure-sensitive adhesive, ethylene-vinyl acetate copolymer, and the like; it may also be a polyacrylic: acrylic resin, carboxyvinyl-sucrose, carboxyvinyl-pentaerythritol copolymer, polyacrylate pressure-sensitive adhesive and the like; or polyoxyethylenes: polyesters such as polyoxyethylene fatty acid esters and polyoxyethylene-polyoxypropylene copolymers: polylactic acid, polyglycolide-lactide, polynearyl dinonyl sebacate, polycyanoalkyl amino ester, polyether polyurethane, and the like. Therefore, the immune response of the human body to the glucose monitoring probe 1 can be inhibited, and the service life of the glucose monitoring probe 1 is prolonged.
Additionally, in some examples, the semi-permeable membrane 130 may also be biocompatible. This can eliminate the use of the biocompatible film 140, thereby reducing the manufacturing cost.
In other examples, the permeability of the formed membrane to the analyte of interest may be adjusted by a modifying agent. For example, hydrophilic modifiers include: polyethylene glycol, hydroxyl or polyhydroxy modifiers. Thus, the biocompatibility of the film formed of the polymer may be increased, thereby replacing the biocompatible film 140.
In this embodiment, the biocompatible membrane 140 may cover the entire glucose monitoring probe 1. In some examples, the biocompatible membrane 140 may cover only the implanted portion 1b of the glucose monitoring probe 1 that is implanted in the body. This can reduce the use of raw materials.
In the present embodiment, the usage period of the glucose monitoring probe 1 may be 1 to 24 days, preferably 7 to 14 days. As described above, the semipermeable membrane 130 can restrict the entry of a part of glucose molecules and electroactive interfering substances, effectively extend the linear range of the glucose monitoring probe 1, and allow the sensing layer 120 to react with glucose oxidase or dehydrogenase more effectively, thereby stabilizing the life cycle of the glucose monitoring probe 1.
In addition, the glucose monitoring probe 1 can also be used in general tests, such as single test or short-time monitoring. For example, the monitoring time may be 1 hour to 24 hours or 24 hours to 36 hours.
In addition, the addition of the biocompatible membrane 140 enables the use period of the glucose monitoring probe 1 to be maintained from 1 day to 24 days, thereby enabling a user to conveniently select the glucose monitor G having the glucose monitoring probe 1 with different use periods according to different needs (e.g., price, etc.).
In the present embodiment, as described above, the glucose monitoring probe 1 may further include the reference electrode 20 and the counter electrode 30 (see fig. 2). Specifically, as shown in fig. 3, the implanted portion 1b of the glucose monitoring probe 1 may include a reference electrode 20 and a counter electrode 30.
In the present embodiment, the glucose monitoring probe 1 implanted in the skin can perform an oxidation-reduction reaction with glucose in interstitial fluid or blood by glucose oxidase or dehydrogenase in the working electrode 10, and form a circuit with the counter electrode 30 to generate a current signal.
In this embodiment, the reference electrode 20 may form a known and fixed potential difference with the interstitial fluid or blood. In this case, the potential difference between the working electrode 10 and the tissue fluid or blood can be measured by the potential difference formed between the reference electrode 20 and the working electrode 10, so that the voltage generated by the working electrode 10 can be accurately grasped. Therefore, the electronic system 2 can automatically adjust and maintain the voltage at the working electrode 10 to be stable according to the preset voltage value, so as to ensure that the measured current signal can accurately reflect the glucose concentration value.
In addition, in the present embodiment, the working electrode 10, the reference electrode 20, and the counter electrode 30 of the implanted portion 1b are arranged in a dispersed manner, but the embodiment of the present invention is not limited thereto, and may include a side-by-side (parallel) arrangement.
In addition, in the present embodiment, the glucose monitoring probe 1 is not limited to a planar probe, but may be a linear probe, a probe having stacked electrodes or layered electrodes, and a probe having coplanar electrodes in which electrodes are provided on the same plane.
In some examples, when the potential difference between the working electrode 10 and the interstitial fluid or blood does not fluctuate much, the reference electrode 20 may not be used.
In the present embodiment, the counter electrode 30 may be made of platinum, silver chloride, palladium, titanium, or iridium. Thereby, the electrochemical reaction at the working electrode 10 can be not affected with good conductivity. However, the present embodiment is not limited thereto, and in other examples, the counter electrode 30 may be made of at least one selected from gold, glassy carbon, graphite, silver chloride, palladium, titanium, or iridium. This can reduce the influence on the working electrode 10 while having good conductivity.
In addition, in some examples, the same material may be used for working electrode 10, counter electrode 30, and reference electrode 20.
In addition, in the present embodiment, the glucose monitoring probe 1 may include two, or three or more electrodes. For example, glucose monitoring probe 1 may include only two electrodes, working electrode 10 and counter electrode 30, and further, glucose monitoring probe 1 may include additional reference electrodes in addition to working electrode 10, reference electrode 20, and counter electrode 30. In this case, it is possible to obtain the potential difference of the working electrode 10 more accurately and grasp the voltage of the working electrode 10, thereby obtaining a more accurate current.
In the present embodiment, as described above, the connection portion 1a of the glucose monitoring probe 1 includes a plurality of contacts (feelers). The number of contacts is equal to the number of electrodes of the implanted portion 1b of the glucose monitoring probe 1. The contact is connected with the electrode of the implanted portion 1b through a lead (wire).
In the present embodiment, as shown in fig. 3, the number of electrodes of the implanted portion 1b of the glucose monitoring probe 1 is three. Accordingly, the connection portion 1a includes three contacts (contact tips), which are a contact 41, a contact 42, and a contact 43, respectively. However, the present embodiment is not limited to this, and for example, the number of electrodes of the implanted portion 1b may be two or more than four electrodes, and accordingly, the connection portion 1a may include two or more than four contacts (contacts).
In the present embodiment, the contact 41, the contact 42, and the contact 43 may each have a disk shape, and may be formed as a pad, for example. In addition, the contact 41, the contact 42, and the contact 43 may be formed as solder points. In other examples, contacts 41, 42, and 43 may also be rectangular, oval, or other irregular shapes.
In the present embodiment, the current signal generated by the implanted portion 1b of the glucose monitoring probe 1 can be transmitted to the contact of the connection portion 1a through the base layer 110 and the transmission wire. That is, the implanted portion 1b of the glucose monitoring probe 1 is connected to the connection portion 1a, and the connection portion 1a is connected to the electronic system 2 via a plurality of contacts, so that the current signal obtained by the working electrode 10 is transmitted to the electronic system 2 through the contacts of the connection portion 1a for analysis. The electronic system 2 can analyze and process the current signal to obtain a glucose concentration signal.
Additionally, in some examples, the electronic system 2 may transmit to an external reading device via wireless communication, such as bluetooth, wifi, etc. A reading device (not shown) may receive the glucose concentration signal emitted by the electronic system 2 and display the glucose concentration value. Further, since the glucose monitoring probe 1 according to the present embodiment can realize continuous monitoring, it is possible to continuously monitor the glucose concentration value of the human body for a long period of time (for example, 1 to 24 days). Additionally, in some examples, the reading device may be a reader or a cell phone APP.
In addition, in this embodiment, the glucose monitoring probe 1 and the electronic system 2 may not require calibration during in vivo use. In addition, the glucose monitoring probe 1 and the electronic system 2 may be calibrated in advance at the time of factory shipment. Thus, the user's hassle of periodically calibrating the monitoring system by finger blood can be eliminated and the potential source of monitoring module reading errors during use reduced.
In the present embodiment, the electronic system 2 may be made of a flexible PCB and a flexible battery. Therefore, the skin can be attached to the skin, and the influence on the daily life of the user is reduced. In some examples, the outer shape of the electronic system 2 may be circular. In addition, in some examples, the electronic system 2 may also have a waterproof housing and a waterproof band-aid, thereby enabling use without affecting daily activities such as swimming or bathing.
In the present embodiment, the glucose monitoring probe 1 can acquire the glucose concentration in interstitial fluid or blood. However, the present embodiment is not limited to this, and for example, by changing the sensor layer 120 on the glucose monitoring probe 1, it is possible to acquire body fluid component data other than glucose, and body fluid components such as acetylcholine, amylase, bilirubin, cholesterol, chorionic gonadotropin, creatine kinase, creatine, creatinine, DNA, fructosamine, glucose, glutamine, growth hormone, ketone body, lactate, oxygen, peroxide, prostate-specific antigen, prothrombin, RNA, thyroid stimulating hormone, troponin, and the like.
In other examples, the concentration of a drug in a bodily fluid may also be monitored, such as antibiotics (e.g., gentamicin, vancomycin, and the like), digitoxin, digoxin, theophylline, and warfarin (warfarin), among others.
In this embodiment, first, the sensing layer 120 is formed on the underlayer 110 of the working electrode 10, then the semipermeable membrane 130 coating is formed on the sensing layer 120, and finally the biocompatible membrane 140 layer is formed on the semipermeable membrane 130 coating. Therefore, the service life of the glucose monitoring probe 1 is prolonged, the interference of other factors is reduced, and the reaction speed of the glucose monitoring probe 1 to glucose is increased.
Hereinafter, a method of manufacturing the working electrode 10 of the glucose monitoring probe 1 will be described in detail with reference to the drawings.
Fig. 8 is a flowchart illustrating a method for manufacturing the working electrode 10 of the glucose monitoring probe 1 according to the embodiment of the present invention. Fig. 9 is a flowchart illustrating a method for manufacturing the semipermeable membrane 130 of the working electrode 10 of the glucose monitoring probe 1 according to the embodiment of the present invention.
In the present embodiment, the method for manufacturing the working electrode 10 of the glucose monitoring probe 1 may include (see fig. 8): preparing a flexible substrate and forming a base layer 110 on the flexible substrate (step S110); preparing a sensing layer 120 reagent including a metal polymer, a glucolase, carbon nanotubes 121, and a cross-linking agent (step S120); coating a sensing layer reagent on the base layer 110 and forming a sensing layer 120 (step S130); forming a semi-permeable membrane 130 for controlling a passing rate of glucose molecules on the sensing layer 120 (step S140); and a biocompatible membrane 140 is formed on the semi-permeable membrane 130 (step S150). In this case, the carbon nanotubes 121 are contained in the sensing layer 120. Therefore, the working voltage of the working electrode 10 is reduced, the interference of other factors is reduced, the reaction sensitivity of the probe to the glucose is improved, the linear range of the response of the glucose monitoring probe 1 to the glucose can be enlarged, and the service life of the probe is prolonged.
As described above, in step S110, a flexible substrate is prepared, and the base layer 110 is formed on the flexible substrate. In some examples, the base layer 110 may also be fabricated by one or more of electroplating, evaporation, printing, or extrusion, among others.
In the present embodiment, in step S130, the sensing layer 120 may be a glucose oxidase sensing layer or a glucose dehydrogenase sensing layer.
In the manufacturing method according to the present embodiment, as shown in fig. 9, the step S140 may include forming the interference suppression layer 132 on the sensor layer 120 (step S141), and further forming the diffusion control layer 131 on the interference suppression layer (step S142). Thus, the tissue fluid or blood component passing through the semipermeable membrane 130 can be reduced by the interference prevention layer 132, and the interfering substance can be blocked outside the semipermeable membrane 130 by the diffusion control layer 131.
In some examples, in step S140, the order of step S141 and step S142 may be interchanged. That is, the diffusion-controlling layer 131 may be first formed on the glucose oxidase or dehydrogenase layer (step S142), and then the tamper-resistant layer 132 may be formed on the diffusion-controlling layer 131 (step S141). Therefore, the interference of impurities on the working electrode 10 can be reduced, the inaccurate detection result can be prevented, and the service life of the glucose monitoring probe 1 can be prolonged.
While the present invention has been described in detail in connection with the drawings and the examples, it is to be understood that the above description is not intended to limit the present invention in any way. The present invention may be modified and varied as necessary by those skilled in the art without departing from the true spirit and scope of the invention, and all such modifications and variations are intended to be included within the scope of the invention.
Claims (5)
1. A working electrode of a glucose monitoring probe is characterized in that,
the disclosed device is provided with:
a base layer formed on a flexible substrate;
a sensing layer formed on the base layer by coating a sensing layer reagent, the sensing layer reagent being capable of chemically reacting with glucose, the sensing layer reagent including a metal polymer, a glucosidase, a carbon nanotube and a cross-linking agent, the carbon nanotube having a hollow columnar shape, the carbon nanotube adsorbing the metal polymer and the glucosidase, the sensing layer reagent including an amino group modification added to the carbon nanotube, the metal polymer being covalently bonded to the carbon nanotube;
a semi-permeable membrane formed on the sensing layer, controlling the passage rate of glucose molecules; and
a biocompatible membrane formed on the semi-permeable membrane.
2. The working electrode of claim 1,
the semi-permeable membrane includes a diffusion controlling layer that controls diffusion of glucose molecules.
3. The working electrode of claim 1,
the semi-permeable membrane includes an anti-interference layer that blocks non-glucose species.
4. The working electrode of claim 1,
the thickness of the sensing layer is 0.1 μm to 100 μm.
5. The working electrode of claim 1,
the service life of the probe is 1 to 24 days.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201920980661 | 2019-06-24 | ||
CN2019209806613 | 2019-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN211785300U true CN211785300U (en) | 2020-10-27 |
Family
ID=70942242
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010246108.4A Active CN111248924B (en) | 2019-06-24 | 2020-03-31 | Working electrode of glucose monitoring probe and manufacturing method thereof |
CN202310491733.9A Pending CN116807469A (en) | 2019-06-24 | 2020-03-31 | Working electrode of glucose monitoring probe for reducing interference |
CN202020454895.7U Active CN211785300U (en) | 2019-06-24 | 2020-03-31 | Working electrode of glucose monitoring probe |
CN202310490287.XA Pending CN116473552A (en) | 2019-06-24 | 2020-03-31 | Method for manufacturing working electrode of glucose monitoring probe |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010246108.4A Active CN111248924B (en) | 2019-06-24 | 2020-03-31 | Working electrode of glucose monitoring probe and manufacturing method thereof |
CN202310491733.9A Pending CN116807469A (en) | 2019-06-24 | 2020-03-31 | Working electrode of glucose monitoring probe for reducing interference |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310490287.XA Pending CN116473552A (en) | 2019-06-24 | 2020-03-31 | Method for manufacturing working electrode of glucose monitoring probe |
Country Status (1)
Country | Link |
---|---|
CN (4) | CN111248924B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111248924A (en) * | 2019-06-24 | 2020-06-09 | 深圳硅基传感科技有限公司 | Working electrode of glucose monitoring probe and manufacturing method thereof |
WO2024021843A1 (en) * | 2022-07-24 | 2024-02-01 | 深圳硅基传感科技有限公司 | Sensor for monitoring lactic acid, and manufacturing method therefor |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116297765A (en) * | 2020-09-01 | 2023-06-23 | 深圳硅基传感科技有限公司 | Polymer membrane for biosensor |
CN112057084A (en) * | 2020-09-07 | 2020-12-11 | 浙江大学 | Double-sided screen printing electrode based on flexible plastic substrate and method thereof |
CN112630283B (en) * | 2020-12-18 | 2023-01-17 | 河南城建学院 | Application of (E, E) -1,1' -bis (2-pyridine vinyl) ferrocene as electrochemical sensor |
CN113325058A (en) * | 2021-04-29 | 2021-08-31 | 苏州中星医疗技术有限公司 | Implantable glucose biosensor and preparation method thereof |
CN113311033A (en) * | 2021-04-29 | 2021-08-27 | 苏州中星医疗技术有限公司 | Lactate biosensor |
CN113567522A (en) * | 2021-08-25 | 2021-10-29 | 上海微创生命科技有限公司 | Biosensor and preparation method thereof |
CN113720889A (en) * | 2021-09-02 | 2021-11-30 | 苏州中星医疗技术有限公司 | Glucose biosensor and glucose biosensing membrane thereof |
CN114002293B (en) * | 2021-11-22 | 2024-01-30 | 深圳硅基传感科技有限公司 | Analyte monitoring probe |
CN114460147A (en) * | 2022-02-11 | 2022-05-10 | 深圳市溢鑫科技研发有限公司 | Vertical graphene electrochemical microelectrode structure |
CN116087286A (en) * | 2023-03-10 | 2023-05-09 | 上海微创生命科技有限公司 | Biosensor and preparation method and application thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6413393B1 (en) * | 1999-07-07 | 2002-07-02 | Minimed, Inc. | Sensor including UV-absorbing polymer and method of manufacture |
WO2007003513A1 (en) * | 2005-07-01 | 2007-01-11 | Cinvention Ag | Process for the production of porous reticulated composite materials |
CN100594379C (en) * | 2007-06-29 | 2010-03-17 | 浙江大学 | Carbon nano tube modified blood sugar biosensor |
JP4951451B2 (en) * | 2007-09-27 | 2012-06-13 | 富士フイルム株式会社 | Carbon nanotube layer-containing structure |
CN101530327B (en) * | 2009-04-20 | 2012-09-05 | 湖州美奇医疗器械有限公司 | Needle amperometric determination type glucose sensor for subcutaneous tissue real-time monitoring and manufacturing method thereof |
CN103995033A (en) * | 2014-05-29 | 2014-08-20 | 天津大学 | Electrochemical glucose sensor based on modification of graphene and nano-particle and application thereof |
CN205607915U (en) * | 2016-03-25 | 2016-09-28 | 中国科学院重庆绿色智能技术研究院 | Glucose sensor based on three -dimensional graphite alkene |
CN105943058B (en) * | 2016-05-19 | 2019-02-05 | 浙江大学 | Flexible electrochemical electrode, continuous glucose monitoring sensor and preparation method thereof |
CN109406589B (en) * | 2018-11-23 | 2023-07-21 | 浙江大学 | Implantable blood glucose test probe and manufacturing method thereof based on screen printing |
CN111248924B (en) * | 2019-06-24 | 2023-04-25 | 深圳硅基传感科技有限公司 | Working electrode of glucose monitoring probe and manufacturing method thereof |
-
2020
- 2020-03-31 CN CN202010246108.4A patent/CN111248924B/en active Active
- 2020-03-31 CN CN202310491733.9A patent/CN116807469A/en active Pending
- 2020-03-31 CN CN202020454895.7U patent/CN211785300U/en active Active
- 2020-03-31 CN CN202310490287.XA patent/CN116473552A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111248924A (en) * | 2019-06-24 | 2020-06-09 | 深圳硅基传感科技有限公司 | Working electrode of glucose monitoring probe and manufacturing method thereof |
WO2024021843A1 (en) * | 2022-07-24 | 2024-02-01 | 深圳硅基传感科技有限公司 | Sensor for monitoring lactic acid, and manufacturing method therefor |
Also Published As
Publication number | Publication date |
---|---|
CN116473552A (en) | 2023-07-25 |
CN116807469A (en) | 2023-09-29 |
CN111248924A (en) | 2020-06-09 |
CN111248924B (en) | 2023-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN211785300U (en) | Working electrode of glucose monitoring probe | |
CN209878658U (en) | Glucose monitoring probe and working electrode thereof | |
Johnston et al. | Advances in biosensors for continuous glucose monitoring towards wearables | |
US7979103B2 (en) | Catheter-free implantable needle biosensor | |
CN110799651A (en) | Method and apparatus for analyte detection using an electrochemical biosensor | |
CN110186976B (en) | Working electrode of glucose monitoring probe and manufacturing method thereof | |
US20100049021A1 (en) | Devices, systems, methods and tools for continuous analyte monitoring | |
US20080312518A1 (en) | On-demand analyte monitor and method of use | |
US20090131778A1 (en) | Devices, systems, methods and tools for continuous glucose monitoring | |
CN113340970A (en) | Electrochemical parameter-based factory calibration method for glucose sensor | |
CN112710713B (en) | Implanted glucose monitoring probe | |
WO2008116017A1 (en) | Continuous analyte monitor with multi-point self-calibration | |
US20120252046A1 (en) | Transdermal systems, devices, and methods for biological analysis | |
CN112438704B (en) | Calibration system of physiological parameter monitor | |
CN114002293B (en) | Analyte monitoring probe | |
Eguílaz et al. | Personal blood glucose analyzers | |
Newman et al. | Biosensors for monitoring glucose | |
WO2022164940A1 (en) | Systems, devices, and methods related to ketone sensors | |
Fragkou et al. | Commercial biosensors for diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GR01 | Patent grant | ||
GR01 | Patent grant |